MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13063-025-09406-4

Медицинская библиотека · Trials · 2026

A prospective multicentre double-blind randomized controlled trial evaluating clinical, cognitive and neural effects of potentiation of electroconvulsive therapy by repetitive transcranial magnetic stimulation in patients with treatment-resistant depression (STIMAGNECT 2).

Clabeau Léa, Moulier Virginie, Kaczmarek Bastien, Dalmont Marine, Batail Jean-Marie, Bouaziz Noomane, Brunelin Jérôme, Calvet Benjamin, Daudet Christophe, Dollfus Sonia, Domenech Philippe, Drapier Dominique, Galvao Filipe, Gohier Bénédicte, Harika-Germaneau Ghina, Holtzmann Jérôme, Jaafari Nemat, Jalenques Isabelle, Januel Dominique, Kazour François, Laurin Andrew, Letourneur Florian, Pouchon Arnaud, Samalin Ludovic, Sauvaget Anne, Szekely David, Vinckier Fabien, Le Clezio Camille, Compere Vincent, Gérardin Emmanuel, Guillin Olivier, Quesada Pierre, Rothärmel Maud

СтатьяПротокол клинического исследованияПеревод в очереди

Аннотация

BACKGROUND

Major depressive disorder is a leading cause of disability worldwide, with treatment-resistant depression (TRD) affecting approximately one-third of patients and leading to increased morbidity and healthcare costs. Electroconvulsive therapy (ECT) remains a key treatment for TRD, but its efficacy is limited, and it is associated with cognitive side effects and delayed symptom relief. Repetitive transcranial magnetic stimulation (rTMS) shares action mechanisms with ECT and has shown potential in enhancing ECT efficacy in a previous trial. The STIMAGNECT 2 trial aims to evaluate whether an rTMS add-on protocol can improve ECT outcomes in TRD patients after 10 ECT sessions.

METHODS

Eighty patients with TRD will be enrolled in a prospective multicentric double-blind randomized controlled trial. All patients will receive a total of 10 ECT sessions. Patients will be randomly assigned to an active or sham rTMS arm. The rTMS protocol (either active or sham) consists of 5 rTMS sessions over 4 days before the beginning of the ECT protocol, with an additional rTMS session the day before each ECT session from the 6th ECT session onward. The main outcome is the response rate following 10 ECT sessions, defined as the proportion of patients achieving a ≥ 50% reduction in their Hamilton Depression Rating Scale (HAMD, 21 items). Secondary outcomes include changes in depression severity (HAMD and QIDS-SR-16) at baseline, during the protocol (Day 4, Day 19, Day 26) and at the end of the protocol, as well as assessment of side effects (adapted UKU), cognitive function (memory, attention, visuospatial abilities, subjective cognitive complaint), autobiographical memory (TEMPau), and ECT session parameters such as seizure characteristics and anesthetic doses. Additionally, potential changes in regional gray matter density, cortical thickness, brain connectivity, and GABA levels will be compared between groups using several magnetic resonance imaging (MRI) sequences (3D, resting-state functional MRI, magnetic resonance spectroscopy).

DISCUSSION: The aim of this trial is to optimize neurostimulation protocols using the synergistic effects of rTMS and ECT in order to improve the treatment of TRD.

TRIAL REGISTRATION: ClinicalTrials.gov NCT06391723 Id RCB: 2023-A01813-42. The trial was registered on January 30, 2024.

Для цитирования: Clabeau Léa, Moulier Virginie, Kaczmarek Bastien, Dalmont Marine, Batail Jean-Marie, Bouaziz Noomane, Brunelin Jérôme, Calvet Benjamin, Daudet Christophe, Dollfus Sonia, Domenech Philippe, Drapier Dominique, Galvao Filipe, Gohier Bénédicte, Harika-Germaneau Ghina, Holtzmann Jérôme, Jaafari Nemat, Jalenques Isabelle, Januel Dominique, Kazour François, Laurin Andrew, Letourneur Florian, Pouchon Arnaud, Samalin Ludovic, Sauvaget Anne, Szekely David, Vinckier Fabien, Le Clezio Camille, Compere Vincent, Gérardin Emmanuel, Guillin Olivier, Quesada Pierre, Rothärmel Maud. A prospective multicentre double-blind randomized controlled trial evaluating clinical, cognitive and neural effects of potentiation of electroconvulsive therapy by repetitive transcranial magnetic stimulation in patients with treatment-resistant depression (STIMAGNECT 2).. Trials. 2026. DOI: 10.1186/s13063-025-09406-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.